Last reviewed · How we verify

Xeomin — Competitive Intelligence Brief

Xeomin (INCOBOTULINUMTOXINA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholine Release Inhibitor [EPC]. Area: Neuroscience.

marketed Acetylcholine Release Inhibitor [EPC] Neuroscience Live · refreshed every 30 min

Target snapshot

Xeomin (INCOBOTULINUMTOXINA) — Merz Pharms. Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xeomin TARGET INCOBOTULINUMTOXINA Merz Pharms marketed Acetylcholine Release Inhibitor [EPC] 2015-01-01
Nuceiva BOTULINUM TOXIN TYPE A GlaxoSmithKline K.K. marketed Acetylcholine Release Inhibitor [EPC] Synaptosomal-associated protein 25 2019-01-01
Botox ONABOTULINUMTOXINA Allergan marketed Acetylcholine Release Inhibitor [EPC] SNAP-25 2010-01-01
Myobloc RIMABOTULINUMTOXINB Elan Pharm marketed Acetylcholine Release Inhibitor [EPC] 2009-01-01
Botulinum neurotoxin (BTX) Botulinum neurotoxin (BTX) The University of Texas Health Science Center, Houston marketed Neurotoxin; acetylcholine release inhibitor SNARE proteins (SNAP-25, VAMP, syntaxin)
Propolis Propolis Cairo University marketed Acetylcholine Release Inhibitor [EPC]
Botulinum toxin A Botulinum toxin A University of Calgary marketed Neurotoxin; Acetylcholine release inhibitor SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Acetylcholine Release Inhibitor [EPC] class)

  1. BioActive Nutritional, Inc. · 2 drugs in this class
  2. Cairo University · 1 drug in this class
  3. Elan Pharm · 1 drug in this class
  4. GlaxoSmithKline K.K. · 1 drug in this class
  5. HUGEL INC · 1 drug in this class
  6. Merz Pharms · 1 drug in this class
  7. REVANCE THERAPEUTICS, INC. · 1 drug in this class
  8. University Health Network, Toronto · 1 drug in this class
  9. Allergan · 1 drug in this class
  10. University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xeomin — Competitive Intelligence Brief. https://druglandscape.com/ci/incobotulinumtoxina. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: